News about Drug Discovery & Development

Sun Pharma, Moebius Medical Anti-Osteoarthritis Injection Offers Sustained Pain Relief in Clinical Trials

Sun Pharmaceutical Industries and Moebius Medical have presented data demonstrating the durability of pain relief achieved in symptomatic knee OA patients through 26 weeks post injection of MM-II.

Drug Discovery & Development | 15/06/2024 | By Aishwarya |  656

Glenmark Gets ANDA Approval for Esomeprazole Magnesium Delayed-Release Capsules

Glenmark has secured final approval by the United States Food & Drug Administration (US FDA) for Esomeprazole Magnesium Delayed-Release Capsules.

Drug Discovery & Development | 15/06/2024 | By Aishwarya |  410

Akums Launches Rabeprazole + Levosulpiride SR Capsules

Akums Akums Drugs & Pharmaceuticals Ltd. announced that it has launched Rabeprazole + Levosulpiride SR Capsules. Approved by the Drug Controller General of India (DCGI), the company claims this new formulation aims to enhance relief for patients suffering from gastrointestinal tract (GIT) disorders.

Drug Discovery & Development | 14/06/2024 | By Manvi |  950

AbbVie and FutureGen to Develop Next-Gen Therapy for Inflammatory Bowel Disease

AbbVie has signed a license agreement with FutureGen Biopharmaceutical to develop FG-M701, a next-generation TL1A antibody for the treatment of IBD currently in preclinical development.

Drug Discovery & Development | 14/06/2024 | By Aishwarya |  545

Streck, Longhorn Vaccines and Diagnostics to Distribute PrimeStore MTM Globally

Streck has joined forces with Longhorn Vaccines and Diagnostics to distribute its flagship product, PrimeStore Molecular Transport Media (MTM), worldwide.

Drug Discovery & Development | 12/06/2024 | By Aishwarya |  346

ALZpath Signs Licensing Deal with Roche for Use of pTau217 Antibody in Blood Test

ALZpath, Inc. has signed a strategic license agreement with Roche for the use of the ALZpath pTau217 antibody to develop and commercialize an Alzheimer's disease diagnostic blood test.

Drug Discovery & Development | 11/06/2024 | By Aishwarya |  947

Amneal Expands Broad Injectables Portfolio with Addition of Six New Therapies

Amneal Pharmaceuticals has expanded its injectables portfolio with six new injectable product launches during the second quarter of 2024.

Drug Discovery & Development | 11/06/2024 | By Aishwarya |  668

Orchid Pharma Gets DCGI Approval for Enmetazobactam

Orchid Pharma has secured Drugs Controller General of India (DCGI) approval for the manufacturing and marketing of its invented New Chemical Entity Active Pharmaceutical Ingredient (API), Enmetazobactam.

Drug Discovery & Development | 10/06/2024 | By Aishwarya |  854

Saghmos Gets US Patent for Phase 3-Ready Cardiorenal Metabolic Modulator

Saghmos Therapeutics, Inc. has announced that the US Patent and Trademark Office (USPTO) has granted US Patent No. 11,986,473 titled, 'Prevention and/or Treatment of Contrast-Induced Acute Kidney Injury' for its Phase 3-ready product, ST-62516.

Drug Discovery & Development | 06/06/2024 | By Aishwarya |  638

Lupin Gets Tentative Approval from US FDA for Letermovir Tablets

Lupin has secured a tentative approval from the United States Food and Drug Administration (US FDA) for its Abbreviated New Drug Application for Letermovir Tablets, 240 mg and 480 mg, to market a generic equivalent of Prevymis Tablets, 240 mg and 480 mg, of Merck Sharp & Dohme LLC.

Drug Discovery & Development | 05/06/2024 | By Aishwarya |  1214